FORM PTO-144	9 (Modified)		Attorney Docket No.: 01	19829000310	Application No.	: 09/546,573		
	NTS AND PUBLI		Applicant: HOLTEN-Al	NDERSEN, Mads	3000			
	INFORMATION Use several sheets		Filing Date: April 10, 20	000	Group: 1643	* 5		
Reference Desig	nation		Page 1					
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Fiting Date (If Appropriate)		
SPA	5,324,634	06/28/94	Zucker	435	7.23			
	4		-					
MAR 3 D 2001	8	FOR	EIGN PATENT DOCU	MENTS				
MAR 3	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)		
THADEMAN.								
	ОТ	HER ART (Inclu	iding Author, Title, Date	e, Pertinent Pages,	Etc.)			
_ <i>sn</i> _ _{AC}	Baker et al., "Ser 70:506-512 (199		nases and their Inhibitors:	Markers for Malig	nant Potential," Br.	J. Cancer		
<u>Se</u> AD	Birkedal-Hansen 4:197-250 (1993		etalloproteinases: A Revi	ew," Critical Reviev	ws in Oral Biology (and Medicine		
<u>SR</u> AE			clonal Antibodies Agains ted Immunosorbent Assay					
SR_AF	Cooksley et al., "Immunoassays for the Detection of Human Collagenase, Stromelysin, Tissue Inhibitor of Metalloproteinases (TIMP) and Enzyme-Inhibitor Complexes," <i>Matrix</i> 10:285-291 (1990)							
<u>SR</u> AG	Cooper et al., "Platelet-derived Collagenase Inhibitor: Characterization and Subcellular Localization," <i>Proc. Natl. Acad. Sci. USA</i> 82:2779-2783 (1985)							
_SR_AH	DeClerck et al., "Inhibition of Invasion and Metastasis in Cells Transfected with an Inhibitor of Metalloproteinases," Cancer Research 52:701-708 (1992)							
_SR_AI	Fujimoto et al., "A One-step Sandwich Enzyme Immunoassay for Tissue Inhibitor of Metalloproteinases-2 Using Monoclonal Antibodies," Clinica Chimica Acta 220:31-45 (1993)							
<u>Se</u> AJ	Goldberg et al., "Interaction of 92-kDa Type IV Collagenase with the Tissue Inhibitor of Metalloproteinases Prevents Dimerization, Complex Formation with Interstitial Collagenase, and Activation of the Proenzyme with Stromelysin," The Journal of Biological Chemistry 267:4583-4591 (1992)							
Se AK	Hembry et al., "Immunolocalization of Tissue Inhibitor of Metalloproteinases (TIMP) in Human Cells Characterization and Use of a Specific Antiserum," J. Cell. Sci. 73:105-119 (1985)							
_SR_AL	Holten-Anderser	n et al., "Quantitat	ion of TIMP-1 in Plasma (80:495-503 (1999)			vith Advanced		
SE AM	Jung et al., "Mat	rix Metalloprotein es-1/Tissue Inhib	ases 1 and 3, Tissue Inhibitor in Plasma of Patients					
Sn AN			n Should be Selected for inica Acta 254:97-100 (199		Inhibitor of Metalle	oproteinases-1		
<u>SR</u> AO		e of Specimen Col Chemistry 42:204	lection in Preanalytical Va 3-2045 (1996)	ariation of Metallop	roteinases and Thei	r Inhibitors in		
<u></u> AP	Metalloproteinas	ses 1 (TIMP-1), an	of Matrix Metalloprotein d MMP-1/TIMP-1 Comp ersus Other Surrogate Ma	lex in Rheumatic Di	sease. Correlation	with Clinical		
<u>Se</u> AQ			ization and Release of Hu Granules," <i>Biochem. J.</i> 28		atinase, Confirming	the Existence		
AR			e of tissue inhibitor of me urnal of Neuro-Oncology		specific aspects of o	cancer		

FORM PTO-144	49 (Modified)	Attorney Docket No.: 019829000310	Application No.: 09/546,573						
	NTS AND PUBLICATIONS FOR	Applicant: HOLTEN-ANDERSEN, Mads							
ľ	INFORMATION DISCLOSURE Use several sheets if necessary)	Filing Date: April 10, 2000	Group: 1643						
SP AS	1) in B16-F10 Melanoma Cells." Journal of the National Cancer Institute 84:1017-1021 (1992)								
SR AT	Khokha et al., "Up-regulation of TIMP-1 Expression in B16-F10 Melanoma Cells Suppresses their Metastatic Ability in Chick Embryo," Clin. Exp. Metastasis 10:365-370 (1992)								
MAR 3SE AU E	Kleiner et al., "Stability Analysis of	of Latent and Active 72-kDA Type IV Collager "Biochemistry 32:1583-1592 (1993)	nase: The Role of Tissue Inhibitor						
TA TRADENTE	Kodama et al., "A Sandwich Enzy Matrix 9:1-6 (1989)	me Immunoassay for Collagenase Inhibitor Us	ing Monoclonal Antibodies,"						
AW	Liotta et al., "Cancer Metastasis ar 64:327-336 (1991)	d Angiogenesis: An Imbalance of Positive and	d Negative Regulation," Cell						
SR AX		ributions of Tumor and Stromal Matrix Metallo and Metastasis Reviews 14:351-362 (1995)	oproteinases to Tumor Progression,						
SR AY	Matrisian, "The Matrix-Degrading	Metalloproteinases," BioEssays 14:455-463 (1	992)						
SR AZ	Mimori, "Clinical Significance of Journal of Cancer 76:531-536 (19	Mimori, "Clinical Significance of Tissue Inhibitor of Metalloproteinase Expression in Gastric Carcinoma," British							
£? _BA	Moll et al., "Tumor Promoter-stimulated M _r 92,000 Gelatinase Secreted by Normal and Malignant Human Cells: Isolation and Characterization of the Enzyme from HT1080 Tumor Cells," Cancer Research 50:6162-6170 (1990)								
<u>Sb_</u> _BB	Moutsiakis et al., "Characterization of Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Plasma," Connective Tissue Research 28:213-230 (1992)								
Sr BC	Murphy et al., "The N-Terminal Domain of Tissue Inhibitor of Metalloproteinases Retains Metalloproteinase Inhibitor Activity," <i>Biochemistry</i> 30:8097-8102 (1991)								
SR BD	Stetler-Stevenson et al., "Matrix metalloproteinases and Tumor Invasion: from Correlation and Causality to the Clinic," Seminars in Cancer Biology 7:147-154 (1996)								
SR BE		hibitor of Metalloproteinases (TIMP-2) A New Biological Chemistry 264:17374-17378 (1989)							
SR_BF	Stetler-Stevenson et al., "Extracell metastasis," <i>The FASEB Journal</i> 7	ular matrix 6: Role of matrix metalloproteinas::1434-1441 (1993)	es in tumor invasion and						
SP BG	Thorgeirsson et al., "Tumor invasi	on, proteolysis, and angiogenesis," Journal of I	Neuro-Oncology 18:89-103 (1994)						
SR BH	Welgus et al., "Human Skin Fibroblast Collagenase: Interaction with Substrate and Inhibitor," Collagen Rel. Res. 5:167-179 (1985)								
_se_bi	Wilhelm et al., "SV40-transformed Human Lung Fibroblasts Secrete a 92-kDA Type IV Collagenase Which Is Identical to That Secreted by Normal Human Macrophages," <i>The Journal of Biological Chemistry</i> 264:17213-17221 (1989)								
_SR BJ	Zucker et al., "Plasma Assay of Ge 76:700-708 (1995)	Zucker et al., "Plasma Assay of Gelatinase B: Tissue Inhibitor of Metalloproteinase Complexes in Cancer," Cancer							
 									
EXAMINER	1 Randa	DATE CONSIDERED 7/17/0/							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		101 B E							
FORM PTO-144		$\mathcal{L}_{\mathcal{E}}$	Attorney Docket No.: 019829000310 Application No.: 09/546,573						
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE			Applicant: Holten-Andersen, Mads et al.						
APPLICANT'S	INFORMATION	DISCLOSURE	Filing Date: April 10, 2000	Group: 1642	8 14				
	Use several sheets			_	<u> </u>				
Reference Desig	nation	Ţ <u>.</u>	J.S. PATENT DOCUMENT	CS .		Page 1			
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)			
AA									
AB									
AC									
AD									
AE									
AF									
AG									
AH									
AI .									
AJ									
AK									
AL									
	FOREIGN PATENT DOCUMENTS								
	Document No.	Date	Country	-Class-	-Sub-class	T ranslation (Yes/No)			
<u>5</u> ? AM	PA 1999 00476	09 April 1999	Denmark						
AN									
AO			·						
AP									
AQ									
AR									
					<u></u>				
	.00	HER ART (Inclu	ıding Author, Title, Date, P	ertinent Pages, I	Etc.)				
<u>SR</u> AS	International Sea	arch Report for Int	ernational Application No. Po	CT/DK 00/0170 c	lated 10 August 20	000			
AT									
AU			·	-					
AV									
AW									
		,							
EXAMINER	1 Raula		DATE CONSIDERED	7/17/01					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ed to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are nature Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	Complete if Known			
Application Number	09/546,573			
Filing Date	04-10-2000			
First Named Inventor	Mads Holten-Andersen et al.		Ŀ۱	
Group Art Unit	1642		FI,	∨ ⊏
Examiner Name	S. Rawlings			0001
Attorney Docket Number	59866.000002	AUG	12 3	2001

			U.S. PATENT DOCUM	MENTS	TECH CEN	TER 1600/2900
		U.S. Patent Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials *	Cite No. ¹	Number Kind Code ² (if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	
	U1	5,324,634	Zucker	06-28-1994		1

AUG 2 1 2007

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	For Office ³	eign Patent Doo Number ⁴	cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	*For
SR	F1	_	9738314	WO	Miller et al.	10-16-1997		_

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7 2				
SR	P1	National Library of Medicine, PubMed Website, "Serum levels of a tissue inhibitor of metalloproteinases-1 (TIMP-1) in bladder cancer patients", Naruo S et al., Int J Urol, Vol. 1, No. 3 September 1994, pp. 238-231, see abstract	_				
SR	P2	National Library of Medicine, PubMed Website, "Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation", Henriet P. et al., APMIS , Vol. 109, No. 1, January 1999, pp. 111-119, see abstract					
5k	P3	Patent Abstracts of Japan, JP8136548 A, Morinaga, 05-31-1996					
JR	P4	Dialog Information Services, File 159, Cancerlit, acession no. 93691448, Guillem JG et al., " Evaluation of tissue inhibitor of metalloproteinase-1 (TIMP-1) as a prognostic marker of human colorectal cancer invation", Proc Annu Meet Am Assoc Cancer Res; 34:A466 1993	_				
SR	P5	Dialog Information Services, File 159, Cancerlit, accession no. 96647008, "Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases" Clin Cancer Res; 1(8): 899-906 1995 Zeng Z et al.	_				

Examiner Signature	•	1 Rower	Date Considered	8/25/01

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DÓ NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark hee if English language Translation is attached.